Efficacy and Safety of Afatinib Plus Bevacizumab as First‐Line Treatment for Advanced NSCLC Patients With Epidermal Growth Factor Receptor (EGFR) Mutations: A Multicenter, Phase II Trial

ABSTRACT:

SUBMITTER: Shi H 

PROVIDER: S-EPMC12336666 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature